Advertisement

Enrollment of Adolescents Aged 16–17 Years Old in Microbicide Trials: An Evidence-Based Approach

      Abstract

      Purpose

      This article explores the ethics and feasibility of enrolling adolescent females in microbicide trials using data from 16- to 17-year-old participants of the Phase 3 trial of the candidate vaginal microbicide, Carraguard.

      Methods

      Secondary analysis was conducted to compare health, behavioral, and operational outcomes between 16- to 17-year-olds and 18- to 19-year-olds screened for and enrolled in the trial. Analytical approaches included Kaplan–Meier survival analysis, Cox proportional hazards modeling, and generalized estimating equations for nonsurvival end points.

      Results

      Results reveal no significant differences between the two age groups for health (sexually transmitted infection, adverse event), risk behavior, or operational (adherence, follow-up) outcomes. However, data suggest that after 1 year of trial participation, human immunodeficiency virus (HIV) and pregnancy incidence were higher and increased more rapidly for the 16- to 17-year-olds than for 18- to 19-year-olds; this finding is entirely consistent with other incidence data for HIV infection among South African youth and cannot be attributed to study participation without a comparison outside the trial.

      Conclusions

      Data from the Carraguard trial provide no evidence that inclusion of 16- to 17-year-olds in the trial had any detrimental effect on trial participants or on the conduct of research. These data provide an argument motivating the inclusion of sexually active adolescents aged 16–17 years into future trials in order to avoid delaying access to an effective product for adolescents at high risk of HIV acquisition. Careful support for adolescent-inclusive protocols (including appropriate counseling) must be incorporated into study design.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Adolescent Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stein Z.A.
        HIV prevention: The need for methods women can use.
        Am J Public Health. 1990; 80: 460-462
        • Greig A.
        • Peacock D.
        • Jewkes R.
        • Msimang S.
        Gender and AIDS: Time to act.
        Aids. 2008; 22: S35-S43
        • UNAIDS
        2012 Report on the global AIDS epidemic.
        UNAIDS, Geneva2012
        • Pettifor A.E.
        • Hudgens M.G.
        • Levandowski B.A.
        • et al.
        Highly efficient HIV transmission to young women in South Africa.
        Aids. 2007; 21: 861-865
        • Shisana O.
        • Rehle T.
        • Simbayi L.
        • et al.
        South African National HIV prevalence, incidence, behaviour and communication survey, 2008: A turning tide among teenagers?.
        HSRC Press, Cape Town2009
        • Pettifor A.E.
        • van der Straten A.
        • Dunbar M.S.
        • et al.
        Early age of first sex: A risk factor for HIV infection among women in Zimbabwe.
        Aids. 2004; 18: 1435-1442
        • Wilson C.M.
        • Wright P.F.
        • Safrit J.T.
        • Rudy B.
        Epidemiology of HIV infection and risk in adolescents and youth.
        J Acquir Immune Defic Syndr. 2010; 54: S5-S6
        • Karim Q.A.
        • Sibeko S.
        • Baxter C.
        Preventing HIV infection in women: A global health imperative.
        Clin Infect Dis. 2010; 50: S122-S129
        • Jaspan H.B.
        • Cunningham C.K.
        • Tucker T.J.
        • et al.
        Inclusion of adolescents in preventive HIV vaccine trials: Public health policy and research design at a crossroads.
        J Acquir Immune Defic Syndr. 2008; 47: 86-92
        • Rudy B.J.
        • Kapogiannis B.G.
        • Lally M.A.
        • et al.
        Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.
        J Acquir Immune Defic Syndr. 2010; 54: S31-S42
        • McClure C.A.
        • Gray G.
        • Rybczyk G.K.
        • Wright P.F.
        Challenges to conducting HIV preventative vaccine trials with adolescents.
        J Acquir Immune Defic Syndr. 2004; 36: 726-733
        • Gouws E.
        • Stanecki K.A.
        • Lyerla R.
        • Ghys P.D.
        The epidemiology of HIV infection among young people aged 15-24 years in southern Africa.
        Aids. 2008; 22: S5-16
        • Hosek S.G.
        • Zimet G.D.
        Behavioral considerations for engaging youth in HIV clinical research.
        J Acquir Immune Defic Syndr. 2010; 54: S25-S30
        • Cohn L.D.
        • Schydlower M.
        • Foley J.
        • Copeland R.L.
        Adolescents' misinterpretation of health risk probability expressions.
        Pediatrics. 1995; 95: 713-716
        • Singh J.A.
        • Karim S.S.
        • Karim Q.A.
        • et al.
        Enrolling adolescents in research on HIV and other sensitive issues: Lessons from South Africa.
        PLoS Med. 2006; 3: e180
        • MacQueen K.M.
        • Karim Q.A.
        Practice brief: Adolescents and HIV clinical trials: Ethics, culture, and context.
        J Assoc Nurses AIDS Care. 2007; 18: 78-82
        • Kapogiannis B.G.
        • Handelsman E.
        • Ruiz M.S.
        • Lee S.
        Introduction: Paving the way for biomedical HIV prevention interventions in youth.
        J Acquir Immune Defic Syndr. 2010; 54: S1-S4
        • Nelson R.M.
        • Lewis L.L.
        • Struble K.
        • Wood S.F.
        Ethical and regulatory considerations for the inclusion of adolescents in HIV biomedical prevention research.
        J Acquir Immune Defic Syndr. 2010; 54: S18-S24
        • Borek N.
        • Allison S.
        • Caceres C.F.
        Involving vulnerable populations of youth in HIV prevention clinical research.
        J Acquir Immune Defic Syndr. 2010; 54: S43-S49
        • DiClemente R.J.
        • Ruiz M.S.
        • Sales J.M.
        Barriers to adolescents' participation in HIV biomedical prevention research.
        J Acquir Immune Defic Syndr. 2010; 54: S12-S17
      1. Essack, Z., C. Slack, and A. Strode, Overcoming key obstacles to adolescent involvement in HIV vaccine and microbicide trials: a roadmap for stakeholders. 2008, HIV AIDS Vaccines Ethics Group in collaboration with Global Campaign for Microbicides.

        • U.S. Department of Health and Human Services
        • Food and Drug Administration
        • Center for Biologics Evaluation and Research
        Guidance for industry, development of preventive HIV vaccines for use in pediatric populations.
        2006
        • Woodsong C.
        • Macqueen K.
        • Amico K.R.
        • et al.
        Microbicide clinical trial adherence: Insights for introduction.
        J Int AIDS Soc. 2013; 16: 18505
        • Swartz L.
        • Kagee A.
        • Kafaar Z.
        • et al.
        Social and behavioral aspects of child and adolescent participation in HIV vaccine trials.
        J Int Assoc Physicians AIDS Care (Chic). 2005; 4: 89-92
        • Moodley K.
        Microbicide research in developing countries: Have we given the ethical concerns due consideration?.
        BMC Med Ethics. 2007; 8: 10
        • Skoler-Karpoff S.
        • Ramjee G.
        • Ahmed K.
        • et al.
        Efficacy of Carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial.
        Lancet. 2008; 372: 1977-1987
        • Van Damme L.
        • Ramjee G.
        • Alary M.
        • et al.
        Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial.
        Lancet. 2002; 360: 971-977
        • McCormack S.
        • Ramjee G.
        • Kamali A.
        • et al.
        PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, double-blind, parallel-group trial.
        Lancet. 2010; 376: 1329-1337
        • Boerma J.T.
        • Weir S.S.
        Integrating demographic and epidemiological approaches to research on HIV/AIDS: The proximate-determinants framework.
        J Infect Dis. 2005; 191: S61-S67
        • Bongaarts J.
        A framework for analyzing the proximate determinants of fertility.
        Popul Dev Rev. 1978; 4: 105-132
        • de Kock A.
        • Skoler S.
        • Ahmed K.
        • Govender S.
        Enrolling adolescents in research on HIV: Young women must be included.
        PLoS Med. 2006; 3: e537
        • Pettifor A.E.
        • Rees H.V.
        • Kleinschmidt I.
        • et al.
        Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey.
        AIDS. 2005; 19: 1525-1534
        • Karim Q.A.
        • Kharsany A.B.
        • Frohlich J.A.
        • et al.
        Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa.
        Int J Epidemiol. 2011; 40: 922-930
        • Zuma K.
        • Mzolo T.
        • Makonko E.
        Determinants of age at sexual debut and associated risks among South African youths.
        Afr J AIDS Res. 2011; 10: 189-194
        • Zuch M.
        • Mason-Jones A.J.
        • Mathews C.
        • Henley L.
        Changes to the law on consent in South Africa: Implications for school-based adolescent sexual and reproductive health research.
        BMC Int Health Hum Rights. 2012; 12: 3
      2. Mahery, P., P. Proudlock, and L. Jamieson, A guide to the children's act for health professionals - Fourth Edition. 2010, Children's Institute, University of Cape Town: Cape Town.

      3. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, Belmont Report: Ethical principles and guidelines for the protection of human subjects of research. 1979, National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research: Washington D. C.

        • Ellen J.M.
        • Wallace M.
        • Sawe F.K.
        • Fisher K.
        Community engagement and investment in biomedical HIV prevention research for youth: Rationale, challenges, and approaches.
        J Acquir Immune Defic Syndr. 2010; 54: S7-11